AdaptHealth Corp.
AHCOHealthcareNASDAQMedical Devices
Scan Results
Daily timeframePart of the healthcare sector, AdaptHealth Corp. (AHCO) is listed under Medical Devices. The $819.0M market capitalization puts AHCO squarely in small-cap range for its industry. It operates through Sleep Health, Respiratory Health, Diabetes Health, and Wellness at Home segments.
Market Cap
$819.0M
Beta
1.42
P/E (TTM)
—
P/E (Fwd)
-47.78
EPS (TTM)
$-1.82
EPS (Fwd)
$-0.13
ROE
-15.2%
ROA
2.3%
Cash
$43.3M
Total Debt
$2.07B
Free CF
-$80.7M
52W Change
-36.0%
Annual Financials
Cash vs Debt
Where AHCO stands vs its 150-day and 200-day moving averages
As of the October 16, 2026 close, AHCO finished 30.62% below its 150-day moving average ($9.21) and 32.24% below its 200-day moving average ($9.43). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is AHCO overbought or oversold?
At the October 16, 2026 close, AHCO's RSI(14) was 82.9, in overbought territory (above 70). The MACD histogram was positive, so short-term momentum leaned bullish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
AdaptHealth Corp. carries $2.07B in total debt against $43.3M in cash reserves — debt is roughly 47.7x the cash position. Managing this leverage effectively will be important for long-term financial stability. Free cash flow is running at -$80.7M, which bears watching. Negative free cash flow can be acceptable during heavy investment periods but needs to improve over time. ROE of -15.2% points to negative capital efficiency, indicating how much profit the company produces per dollar of shareholder equity. ROA of 2.3% is on the lower side, which is common in asset-heavy industries. Revenue has been relatively flat, moving from $2.97B (2022) to $3.24B (2025).
The debt-to-cash ratio suggests meaningful leverage on the balance sheet, a factor worth monitoring if credit conditions tighten. The company is burning cash at the operating level, which is not unusual for growth-phase companies but adds risk if it persists. It is important to consider these factors alongside broader market conditions and individual financial goals when reviewing AHCO.